Market Overview

Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO

Share:

— Experienced Leader Brings Extensive Record of Global Strategic and
Commercial Operational Accomplishments and Successful Product Launches —

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced the appointment of Jayson Dallas, M.D., as President and
Chief Executive Officer. Dr. Dallas, a biotech and pharmaceutical
industry executive with decades of global strategic and commercial
experience, will join Aimmune as President and CEO on June 19th, and
will also become a member of the Aimmune Board of Directors.

Dr. Dallas succeeds Stephen Dilly, M.B.B.S., Ph.D., who announced his
planned retirement late last year. Dr. Dilly will serve as a Special
Advisor to Aimmune through the end of 2018 as Aimmune prepares for
regulatory filings for AR101, its investigational biologic oral
immunotherapy for desensitization of patients with peanut allergy.

"Jayson comes to Aimmune with both the physician's focus on patient
well-being and the commercial executive's vision of how to build,
innovate and deliver. With these attributes, we believe he'll capably
lead Aimmune to become a commercial company and advance additional food
allergy therapeutic candidates into clinical development. We're pleased
that our comprehensive search led us to Jayson, and we're looking
forward to accompanying and supporting him on the transformative road
ahead," said Mark McDade, Chairman of the Aimmune Board of Directors.
"At the same time, we want to express our gratitude to Stephen, who
guided Aimmune's evolution from an inspired, scrappy start-up to the
standard-bearer in the emerging food allergy therapeutic space. He and
his family have our very best wishes."

Dr. Dallas joins Aimmune from Ultragenyx, a biopharmaceutical company
focused on the development of products for rare and ultra-rare diseases,
where he served as the company's first Chief Commercial Officer. In
nearly three years in that role, he oversaw commercial operations,
including sales, marketing, reimbursement, and new product planning, and
led the launches of Ultragenyx's first two products, both of which
received U.S. Food and Drug Administration (FDA) approvals in the past
year.

Prior to his work at Ultragenyx, Dr. Dallas spent five years with Roche,
as General Manager of Roche in the United Kingdom and as head of global
commercial strategy groups at Genentech, focused on oncology, immunology
and ophthalmology. Earlier, Dr. Dallas headed the specialty medicines
operating unit for Novartis in the United States, after holding several
leadership roles of increasing responsibility within the company. He
also held significant medical and marketing positions as he built his
career at Pfizer, Roche and Proctor & Gamble Pharmaceuticals. Before
joining the pharmaceutical industry, Dr. Dallas practiced medicine in
South Africa and the United Kingdom and worked as a research physician.
Dr. Dallas earned an M.D. from the University of the Witwatersrand in
Johannesburg, South Africa, and he subsequently acquired an MBA from
Ashridge in Berkhamsted, United Kingdom.

"I'm thrilled to step into a company that is delivering on its
commitment to the food allergy community to develop products that can
improve people's lives," said Dr. Dallas. "Throughout my career, I've
been driven by the need to bring effective treatments to patients and
their families. It is an honor to have the opportunity to lead Aimmune
to potentially offer the first treatment intended to protect people with
peanut allergy from life-threatening reactions. I appreciate the
phenomenal work that Stephen has done to build Aimmune into a fully
integrated biotechnology company and I am extremely proud to be taking
over at this exciting time."

In the role of Special Advisor, Dr. Dilly will focus on the execution of
Aimmune's regulatory filings for AR101, which has FDA Fast Track
Designation, as well as FDA Breakthrough Therapy Designation for
peanut-allergic patients ages 4–17. Aimmune plans to submit a Biologics
License Application (BLA) for AR101 to the FDA by the end of 2018,
followed by a Marketing Authorisation Application (MAA) to the European
Medicines Agency (EMA) in the first half of 2019.

"As Aimmune nears the turn toward potentially having its first product
on the market, Jayson is the ideal leader to take the baton," said Dr.
Dilly. "I'm delighted to welcome him to Aimmune, and I'm excited to work
closely with him to provide optimal continuity through the AR101
regulatory process. It has been a privilege to have been entrusted with
building Aimmune and working to alleviate the impact of food allergies.
I can confidently hand that charge over to Jayson, knowing that he will
take it forward with clear-sighted resolve and care."

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for potentially life-threatening food
allergies. The company's Characterized Oral Desensitization
ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels
of protection by desensitizing patients with defined, precise amounts of
key allergens. Aimmune's first investigational biologic product using
CODIT™, AR101 for the treatment of peanut allergy, has received the
FDA's Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4–17 years of age and is currently being
evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding: Aimmune's expectations regarding its new chief
executive officer; Aimmune's expectations regarding the potential
benefits of AR101; Aimmune's expectations regarding potential
applications of the CODIT™ approach to treating life-threatening food
allergies; Aimmune's ability to develop and advance additional product
candidates into and successfully complete clinical trials; and Aimmune's
expectations regarding the timing of potential regulatory filings for
marketing approval of AR101 in the United States and Europe. Risks and
uncertainties that contribute to the uncertain nature of the
forward-looking statements include: the expectation that Aimmune will
need additional funds to finance its operations; the company's ability
to initiate and/or complete clinical trials; the unpredictability of the
regulatory process; the possibility that the results of early clinical
trials may not be predictive of future results; the possibility that
Aimmune's clinical trials will not be successful; Aimmune's dependence
on the success of AR101; the company's reliance on third parties for the
manufacture of the company's product candidates; possible regulatory
developments in the United States and foreign countries; and Aimmune's
ability to attract and retain senior management personnel. These and
other risks and uncertainties are described more fully in Aimmune's most
recent filings with the Securities and Exchange Commission, including
its Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.
All forward-looking statements contained in this press release speak
only as of the date on which they were made. Aimmune undertakes no
obligation to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.

This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or the European Medicines Agency
(EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com